UNSPSC 51142560: Phenglutarimide hydrochloride

This classification denotes an anticholinergic agent with the molecular formula C17H24N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B963BYQ21V, chemically known as 2-(2-diethylaminoethyl)-2-phenylglutarimide hydrochloride, but more generally known as phenglutarimide hydrochloride, which bears US NIH Compound Identifier 102668. European Medicines Agency schedules phenglutarimide hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09762MIG.

Most nations, for tariff purposes, schedule phenglutarimide hydrochloride under HS 29251995. SMILES: CCN(CC)CCC1(CCC(=O)NC1=O)C2CCCCC2.CL.

UNSPSC 51142560 Phenglutarimide hydrochloride is a Commodity code that nominally specifies a single active pharmaceutical ingredient, but the recent state and local opportunities tagged under it show a mismatch with this narrow chemical specification. The three most recent solicitations tracked under this code involve broader pharmaceutical procurement — naloxone and drug deactivation systems, therapeutic pharmacy initiatives for direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. State and local governments buying under this code span county health departments, state health and human services agencies, and cooperative purchasing alliances. Seminole County, Florida's procurement of naloxone and drug deactivation systems represents the most concrete recent activity, while the Texas Health and Human Services Commission and Minnesota's multistate cooperative alliance show state-level and regional purchasing interest in pharmaceutical supply and distribution models.

Seminole County posted IFB 60459723LAS on June 30, 2026, soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building in Sanford, Florida, with responses due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026; the RFP draws participation from multiple states including Oregon and routes products through three authorized wholesalers. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, as a preliminary market-intelligence solicitation exploring direct-to-manufacturer prescription programs without a formal competitive timeline or award value. Activity in this code concentrates in Florida, Texas, and Minnesota, though the code's actual application to a single chemical compound versus the broader pharmaceutical procurement being tagged suggests the code classification does not reflect current state and local buying patterns.